Dyadic regains Nasdaq compliance, achieves $750K in milestones with Proliant & Inzymes

DYADIC INTERNATIONAL INC

Regained compliance with Nasdaq market value ($35M) and bid price ($1.00) rules after 10 consecutive days ending Sept 30 & Oct 2, 2025.
Received $500K milestone from Proliant for recombinant human albumin productivity; payment expected Q4 2025; commercial launch targeted late 2025/early 2026.
Received $250K milestone payment from Inzymes for dairy enzyme productivity improvements; first enzyme scale-up on track for late 2025 launch.
Signed term sheet for development of non-animal human alpha-lactalbumin for infant nutrition; sampling of bovine version underway.
Advancing commercialization of recombinant transferrin and DNase I with ongoing sampling and validation in research/diagnostic markets.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.